MEDICINOVA ANNOUNCES UPDATE AND BASIC CHARACTERISTIC RANDOMIZED PATIENTS’ OF PHASE 2/3 CLINICAL TRIAL OF MN-166 (IBUDILAST) IN ALS (COMBAT-ALS CLINICAL TRIAL) PRESENTED AT THE 36TH INTERNATIONAL SYMPOSIUM ON ALS/MND

Reuters · 1d ago

Please log in to view news